Literature DB >> 12185893

Estimating risk and rate levels, ratios and differences in case-control studies.

Gary King1, Langche Zeng.   

Abstract

Classic (or 'cumulative') case-control sampling designs do not admit inferences about quantities of interest other than risk ratios, and then only by making the rare events assumption. Probabilities, risk differences and other quantities cannot be computed without knowledge of the population incidence fraction. Similarly, density (or 'risk set') case-control sampling designs do not allow inferences about quantities other than the rate ratio. Rates, rate differences, cumulative rates, risks, and other quantities cannot be estimated unless auxiliary information about the underlying cohort such as the number of controls in each full risk set is available. Most scholars who have considered the issue recommend reporting more than just risk and rate ratios, but auxiliary population information needed to do this is not usually available. We address this problem by developing methods that allow valid inferences about all relevant quantities of interest from either type of case-control study when completely ignorant of or only partially knowledgeable about relevant auxiliary population information.

Mesh:

Year:  2002        PMID: 12185893     DOI: 10.1002/sim.1032

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  21 in total

1.  Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.

Authors:  Arduino A Mangoni; Richard J Woodman; Paraskevi Gaganis; Andrew L Gilbert; Kathleen M Knights
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

2.  Gestational age, birth weight, and the risk of hyperkinetic disorder.

Authors:  K M Linnet; K Wisborg; E Agerbo; N J Secher; P H Thomsen; T B Henriksen
Journal:  Arch Dis Child       Date:  2006-06-05       Impact factor: 3.791

3.  Risk of affective and stress related disorders among employees in human service professions.

Authors:  J Wieclaw; E Agerbo; P B Mortensen; J P Bonde
Journal:  Occup Environ Med       Date:  2006-05       Impact factor: 4.402

4.  Effect of psychiatric illness and labour market status on suicide: a healthy worker effect?

Authors:  Esben Agerbo
Journal:  J Epidemiol Community Health       Date:  2005-07       Impact factor: 3.710

Review 5.  Case-control studies in pharmacoeconomic research: an overview.

Authors:  J Jaime Caro; Krista F Huybrechts
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

6.  Adult Connection in Assault Injury Prevention among Male Youth in Low-Resource Urban Environments.

Authors:  Alison J Culyba; Elizabeth Miller; Kenneth R Ginsburg; Charles C Branas; Wensheng Guo; Joel A Fein; Therese S Richmond; Bonnie L Halpern-Felsher; Douglas J Wiebe
Journal:  J Urban Health       Date:  2018-06       Impact factor: 3.671

7.  Fetal growth and schizophrenia: a nested case-control and case-sibling study.

Authors:  Philip Rising Nielsen; Preben Bo Mortensen; Christina Dalman; Tine Brink Henriksen; Marianne Giørtz Pedersen; Carsten Bøcker Pedersen; Esben Agerbo
Journal:  Schizophr Bull       Date:  2012-12-12       Impact factor: 9.306

8.  Psychiatric illness, socioeconomic status, and marital status in people committing suicide: a matched case-sibling-control study.

Authors:  Esben Agerbo; Ping Qin; Preben Bo Mortensen
Journal:  J Epidemiol Community Health       Date:  2006-09       Impact factor: 3.710

9.  Allergy is associated with suicide completion with a possible mediating role of mood disorder - a population-based study.

Authors:  P Qin; P B Mortensen; B L Waltoft; T T Postolache
Journal:  Allergy       Date:  2010-12-08       Impact factor: 13.146

10.  Fractures during growth: potential role of a milk-free diet.

Authors:  J Konstantynowicz; T V Nguyen; M Kaczmarski; J Jamiolkowski; J Piotrowska-Jastrzebska; E Seeman
Journal:  Osteoporos Int       Date:  2007-05-22       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.